Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CelliStem OA-sEV
- Development stage
- Phase 1
- Lead developer
- Cells for Cells
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intrathecal
01
Overview
CelliStem OA-sEV is an exosome-based therapeutic candidate developed by CelliStem for the treatment of osteoarthritis. It consists of small extracellular vesicles (sEVs) derived from mesenchymal stem cells (MSCs) through a proprietary isolation and purification process. These vesicles carry bioactive cargo, including microRNAs and proteins, that exert anti-inflammatory and regenerative effects within the joint. The therapy is designed to be administered via intra-articular injection to modulate the local microenvironment, inhibit inflammatory cytokines, and promote the regeneration of damaged chondrocytes. By targeting the underlying pathophysiology of joint degeneration rather than just providing symptomatic relief, CelliStem OA-sEV aims to offer a disease-modifying approach to osteoarthritis management.
- Brand names
- CelliStem®OA-sEV
- Other names
- MSC-derived small extracellular vesicles
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on CelliStem OA-sEV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CelliStem OA-sEV.